Registered title, quoted from ClinicalTrials.gov
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen Memorial Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06843681, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: women only
Registered eligibility fields
Breast mass ≥2cm, and in situ cancer pathology confirmed HER2 positive (definition: immunohistochemical results 3+ or in situ hybridization results positive);
Inclusion criterion 2
Previous treatment-related toxicity should be alleviated to NCI CTCAE (version 5.0) ≤1 degree, AST and ALT≤2.5 times the upper limit of normal, total bilirubin ≤1.5 times the upper limit of normal;
Inclusion criterion 7
Had received radiotherapy, chemotherapy, endocrine therapy, or was participating in any interventional drug clinical trial within 4 weeks prior to enrollment;
Exclusion criterion 9
Total bilirubin (TBIL) ≤3× upper limit of normal (ULN),
Inclusion criterion 9
Alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤2.5×ULN (patients with liver metastasis ≤5xULN),
Inclusion criterion 10
Serum creatinine ≤1.5×ULN or creatinine clearance (Ccr) ≥60 ml/min;
Inclusion criterion 11
White blood cell count (WBC) ≥3.0×10\^9 / L,
Inclusion criterion 13
Neutrophil count (ANC) ≥1.5×10\^9 / L,
Inclusion criterion 14
Platelet count (PLT) ≥70×10\^9 / L
Inclusion criterion 15
Imaging examination showed at least one measurable lesion within 2 weeks before enrollment;
Inclusion criterion 5
Pregnant or lactating women, women of childbearing age who refused to use effective contraception during the study period;
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06843681, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Diagnosed breast carcinoma in situ (female, 18 to 70 years old);
- Breast mass ≥2cm, and in situ cancer pathology confirmed HER2 positive (definition: immunohistochemical results 3+ or in situ hybridization results positive);
- No evidence of distant transfer;
- Have not received any previous cancer treatment;
- Imaging examination showed at least one measurable lesion within 2 weeks before enrollment;
- Left ventricular ejection fraction (LVEF) was measured by echocardiography ≥50%;
- Previous treatment-related toxicity should be alleviated to NCI CTCAE (version 5.0) ≤1 degree, AST and ALT≤2.5 times the upper limit of normal, total bilirubin ≤1.5 times the upper limit of normal;
- Liver and kidney function tests are basically normal:
- Total bilirubin (TBIL) ≤3× upper limit of normal (ULN),
- Alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤2.5×ULN (patients with liver metastasis ≤5xULN),
- Serum creatinine ≤1.5×ULN or creatinine clearance (Ccr) ≥60 ml/min;
- Adequate bone marrow functional reserve:
- White blood cell count (WBC) ≥3.0×10\^9 / L,
- Neutrophil count (ANC) ≥1.5×10\^9 / L,
- Platelet count (PLT) ≥70×10\^9 / L
- Fertile women must use contraceptives;
- Be able to understand the research process, voluntarily participate in the study, and sign the informed consent.
Exclusion Criteria:
- Metastatic breast cancer (stage IV);
- History of invasive breast cancer, or prior systemic treatment to treat or prevent breast cancer;
- Previous or concurrent malignant diseases, except skin basal cell carcinoma or cervical cancer in situ;
- Patients with severe heart disease or discomfort that is not expected to tolerate chemotherapy, including but not limited to: fatal arrhythmias or higher grade atrioventricular block, unstable angina pectoris, clinically significant valvular disease, transmural myocardial infarction shown by electrocardiogram, uncontrolled hypertension;
- Insufficient bone marrow or kidney function, liver function impairment;
- Grade 2 or more severe peripheral neuropathy;
- Patients with thrombocytopenia, neutropenia, anemia, hypokalemia, and elevation of alanine aminotransferase or aspartate aminotransferase above CTCAE Level 1;
- Patients who are known to be allergic to the active ingredient or other ingredient of the investigational drug;
- Had received radiotherapy, chemotherapy, endocrine therapy, or was participating in any interventional drug clinical trial within 4 weeks prior to enrollment;
- Pregnant or lactating women, women of childbearing age who refused to use effective contraception during the study period;
- Any other conditions that the investigator considers the patient unfit to participate in the study, concomitant diseases or conditions that may interfere with study participation, or any serious medical disorder that may affect the safety of the subject (e.g., uncontrolled heart disease, high blood pressure, active or uncontrollable infection, active hepatitis B virus infection).
Quoted from ClinicalTrials.gov, NCT06843681, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06843681, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.